Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rolapitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
2010-022742-25Phase 3Completed
- Sponsor
- Tesaro, Inc.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Rolapitant + granisetron + dexamethasone with Placebo + granisetron + dexamethasone (2 arms). Primary endpoint: Complete response rate in the delayed phase. Started Feb 2012; status: completed.
02
Drugs
rolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2010-022742-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022742-25.